Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cassava Sciences Inc SAVA

Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on neuroscience. The Company's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. It has two biopharmaceutical assets under... see more

Recent & Breaking News (NDAQ:SAVA)

Cassava Sciences Announces Initiation of an Open-label Extension Study

GlobeNewswire October 13, 2022

Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference

GlobeNewswire September 8, 2022

No Evidence of Data Manipulation in Science Publication on Simufilam

GlobeNewswire August 18, 2022

CASSAVA SCIENCES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Cassava Sciences, Inc. - SAVA

Business Wire August 12, 2022

Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of Open-label Study

GlobeNewswire August 3, 2022

CASSAVA SCIENCES INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Cassava Sciences, Inc. - SAVA

PR Newswire July 29, 2022

Cassava Sciences Responds to Media Reports

GlobeNewswire July 27, 2022

CASSAVA SCIENCES INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Cassava Sciences, Inc. - SAVA

Business Wire July 15, 2022

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Cassava Sciences, Inc.

Newsfile July 7, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

PR Newswire May 11, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

Newsfile May 9, 2022

Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program

GlobeNewswire May 5, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

PR Newswire May 3, 2022

Cassava Sciences Invited to Participate in B. Riley Securities' Neuroscience Conference

GlobeNewswire April 25, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

PR Newswire April 23, 2022

CASSAVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Cassava Sciences, Inc. on Behalf of Cassava Stockholders and Encourages Investors to Contact the Firm

Business Wire April 21, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

Newsfile April 21, 2022

Webcast Details for Cassava Sciences' Upcoming Fireside Chat

GlobeNewswire April 4, 2022

Cassava Sciences Announces Fireside Chat and Presentation Tuesday, April 5th

GlobeNewswire March 30, 2022

Cassava Sciences Reports Full-year 2021 Financial Results and Operating Updates

GlobeNewswire February 28, 2022